Indian Pharma Major Cipla Wins R2 Billion Contract In South Africa

Indian pharma major Cipla has won a R2 billion (South African currency, ZAR) contract from the South African government’s National ARV tender. The company was awarded the contract through its South African subsidiary, Cipla Medpro. The contract will be effective from the April 1, 2015 for a period of three years.

This would be the third such contract that has been awarded to Cipla Medpro this year by . Cipla is known as a pioneer of fixed dose combinations following Cipla’s Dr Yusuf Hamied’s accomplishment of making Aids medication available or a dollar a day in 2001,” said Paul Miller, CEO of Cipla Medpro. The contract is for producing medicines to fight HIV and AIDS.

“We intend to continue this proud tradition and build on the foundation laid to continue our quest of providing affordable healthcare to all,” added Miller.

The company will produce the drug at its Cipla Medpro Manufacturing (CMM), which is based in Kwazulu-Natal. Currently, the company is into producing fixed dose combinations (FDCs) drugs.

“We are extremely proud to have won this tender which is not only testament to our high quality product portfolio, but is also in line with Cipla’s ethos of advancing healthcare for all South Africans. We look forward to continuing this partnership with government - united in the fight against Aids,” stated Subhanu Saxena, managing director and global CEO of Cipla Limited.

Representational Image